|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 121 | 2019 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 122 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 123 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 124 | 2019 | Effectiveness and safety of Tetrahydrocannabinol - Cannabidiol Oromucosal spray in Belgian patients with multiple sclerosis spasticity: a retrospective data collection | POPESCU, Veronica; Vos, C.; van Dael, V.; Raeymaekers, G.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 125 | 2019 | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim; Hengstman, Gerald | Journal Contribution | A1 |
| 126 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 127 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
| 128 | 2019 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis | Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; Ozakbas, Serkan; Kappos, Ludwig; Kuhle, Jens; Terzi, Murat; Lechner-Scott, Jeannette; Boz, Cavit; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela A.; Van Pesch, Vincent; VAN WIJMEERSCH, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; Karabudak, Rana; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut | Journal Contribution | A1 |
| 129 | 2019 | Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD-CD27- Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients | FRAUSSEN, Judith; Marquez, Susanna; Takata, Kazushiro; BECKERS, Lien; MONTES DIAZ, Gwendoline; Zografou, Chrysoula; VAN WIJMEERSCH, Bart; Villar, Luisa M.; O'Connor, Kevin C.; Kleinstein, Steven H.; SOMERS, Veerle | Journal Contribution | A1 |
| 130 | 2019 | Effects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis | FEYS, Peter; MOUMDJIAN, Lousin; VAN HALEWYCK, Florian; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; VAN ASCH, Paul | Journal Contribution | A1 |
| 131 | 2019 | A pilot study of the effects of running training on visuospatial memory in MS: A stronger functional embedding of the hippocampus in the default-mode network? | Huiskamp, Marijn; MOUMDJIAN, Lousin; VAN ASCH, Paul; POPESCU, Veronica; Schoonheim, Menno Michiel; Steenwijk, Martijn D.; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Geurts, Jeroen J. G.; FEYS, Peter; Hulst, Hanneke E. | Journal Contribution | A1 |
| 132 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 13 | 2019 | Walking to Music and Metronome at Various Tempi in Persons With Multiple Sclerosis: A Basis for Rehabilitation | Moens, Bart; Maes, Pieter-Jan; Van Nieuwenhoven, Johan; Leman, Marc; MOUMDJIAN, Lousin; VAN WIJMEERSCH, Bart; FEYS, Peter | Journal Contribution | A1 |
| 14 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 15 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 16 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 17 | 2018 | Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) | Vermersch, Patrick; Coles, Alasdair J.; Boyko, Alexey N.; De Seze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; McCombe, Pamela; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 18 | 2018 | Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) | Steingo, Brian; Oreja-Guevara, Celia; Alroughani, Raed; Brassat, David; Boyko, Alexey N.; McCombe, Pamela; VAN WIJMEERSCH, Bart; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; Vermersch, Patrick | Journal Contribution | M |
| 19 | 2018 | Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) | VAN WIJMEERSCH, Bart; Boyko, Alexey N.; Broadley, Simon; Brassat, David; Dive, Dominique; Hupperts, Raymond M. M.; Lycke, Jan; Montalban, Xavier; Sharrack, Basil; Wray, Sibyl; Margolin, David H.; Chung, Luke; Daizadeh, Nadia; Chirieac, Madalina; Wiendl, Heinz | Journal Contribution | M |
| 20 | 2018 | Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension | VAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H. | Journal Contribution | M |
Loading...
5
0
5
0
false